GLP-1 Receptor Agonist Global Market Report 2026

Description

GLP-1 receptor agonists are medications that stimulate insulin release when blood glucose levels are high and suppress glucagon secretion when blood glucose is low. They are primarily used in the treatment of type 2 diabetes mellitus.

The main drug classes of GLP-1 receptor agonists include liraglutide, dulaglutide, lixisenatide, and others. Liraglutide, for example, works by helping the pancreas release the appropriate amount of insulin in response to elevated blood sugar levels. These drugs are administered via parenteral or oral routes and are used in settings such as hospitals, surgical clinics, and other healthcare facilities.

Tariffs have introduced cost pressures in the glp-1 receptor agonist market by increasing prices of imported active pharmaceutical ingredients, injection devices, and specialized manufacturing equipment. These impacts are most pronounced in injectable segments and in regions dependent on cross-border pharma supply chains such as asia-pacific and europe. However, tariffs are also encouraging localized manufacturing, supply chain diversification, and strategic investments in regional production hubs, supporting long-term market resilience and self-sufficiency.

The glp-1 receptor agonist market research report is one of a series of new reports from The Business Research Company that provides glp-1 receptor agonist market statistics, including glp-1 receptor agonist industry global market size, regional shares, competitors with a glp-1 receptor agonist market share, detailed glp-1 receptor agonist market segments, market trends and opportunities, and any further data you may need to thrive in the glp-1 receptor agonist industry. This glp-1 receptor agonist market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The glp-1 receptor agonist market size has grown strongly in recent years. It will grow from $14.09 billion in 2025 to $14.83 billion in 2026 at a compound annual growth rate (CAGR) of 5.3%. The growth in the historic period can be attributed to rising prevalence of type 2 diabetes, increased awareness of glycemic control therapies, strong clinical efficacy versus traditional antidiabetics, physician preference for incretin-based therapies, favorable reimbursement in developed markets.

The glp-1 receptor agonist market size is expected to see strong growth in the next few years. It will grow to $18.32 billion in 2030 at a compound annual growth rate (CAGR) of 5.4%. The growth in the forecast period can be attributed to growing obesity population, expanding approval for cardiovascular risk reduction, innovation in oral and combination therapies, increased penetration in emerging markets, rising patient preference for weight loss benefits. Major trends in the forecast period include expansion of glp-1 therapies beyond diabetes, rising demand for long-acting and once-weekly formulations, growth of oral glp-1 receptor agonists, increasing focus on weight management indications, strategic partnerships and licensing agreements.

The increasing prevalence of diabetes is expected to drive the growth of the GLP-1 receptor agonist market in the coming years. Diabetes is a chronic condition that occurs when the pancreas produces insufficient insulin or when the body cannot effectively use the insulin it produces, resulting in elevated blood sugar levels. GLP-1 receptor agonists help manage diabetes by stimulating the body to produce more insulin, thereby lowering blood glucose levels. For example, in March 2024, the Office for Health Improvement and Disparities, a UK-based government agency, reported that between March 2022 and March 2023, the percentage of individuals with type 1 diabetes receiving all eight recommended care processes increased by 22%, while for type 2 diabetes, it rose by 21%; the percentage achieving target HbA1c levels reached 37.9%. Therefore, the rising prevalence of diabetes is fueling the growth of the GLP-1 receptor agonist market.

Leading companies in the GLP-1 receptor agonist market are focusing on developing sustained-release GLP-1 receptor agonists to gain a competitive advantage. Sustained-release GLP-1 receptor agonists (GLP-1RAs) gradually release the drug into the bloodstream over time, providing longer-lasting effects and reducing the frequency of injections compared to traditional GLP-1RAs. For example, in April 2023, Mitsubishi Tanabe Pharma Corporation, a Japan-based pharmaceutical company, launched Mounjaro 2.5 mg and 5 mg Ateos. It is the world's first sustained-release GIP/GLP-1 receptor agonist for type 2 diabetes, designed to activate both GLP-1 and GIP receptors. The GLP-1 receptor helps regulate blood sugar levels, while the GIP receptor stimulates insulin secretion and reduces appetite.

In July 2024, Roche, a Swiss-based pharmaceutical company, acquired Carmot Therapeutics for US$2.7 billion, with up to an additional US$400 million in milestone payments. Through this acquisition, Roche aimed to strengthen its metabolic disease franchise by gaining access to Carmot's advanced portfolio, including a Phase-2-ready dual GLP-1/GIP receptor agonist, enhancing its position in the obesity and diabetes markets. Carmot Therapeutics is a U.S.-based biotech company focused on developing incretin-based therapies, including CT-388 (a weekly injectable dual GLP-1/GIP agonist), CT-996 (an oral small-molecule GLP-1 agonist), and another injectable GLP-1/GIP candidate, CT-868.

Major companies operating in the glp-1 receptor agonist market are Novo Nordisk A/S, Sanofi SA, Eli Lilly and Company, AstraZeneca Inc., Boehringer Ingelheim International GmbH, Hanmi Pharm Co. Ltd., Pfizer Inc., Amgen Inc., Innovent Biologics Inc., Jiangsu Hengrui Medicine Co., Sun Pharmaceuticals Industries Ltd., PegBio Co. Ltd., Zealand Pharma A/S, Bristol-Myers Squibb Company, Chongqing Lummy Pharmaceutical Co. Ltd., Daiichi Sankyo Company Limited, Dong-A ST Co. Ltd., Eisai Co. Ltd., HanAll Biopharma Co. Ltd., Ipsen SA, Johnson & Johnson, Merck & Co. Inc., Novartis AG.

North America was the largest region in the GLP-1 receptor agonist market in 2025. Asia-Pacific is expected to be the fastest-growing region in the GLP-1 receptor agonist market report during the forecast period. The regions covered in the glp-1 receptor agonist market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the glp-1 receptor agonist market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The GLP-1 receptor agonist market consists of sales of dulaglutide, bydureon b-cise, exenatide, and semaglutide. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

GLP-1 Receptor Agonist Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses glp-1 receptor agonist market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on end user analysis.
Benchmark performance against key competitors based on market share, innovation, and brand strength.
Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for glp-1 receptor agonist ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The glp-1 receptor agonist market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

Markets Covered:1) By Drug Class: Exenatide; Liraglutide; Dulaglutide; Lixisenatide; Other Drugs
2) By Route Of Administration: Parenteral; Oral
3) By End Users: Hospitals; Surgical Clinics; Other Users
Companies Mentioned: Novo Nordisk A/S; Sanofi SA; Eli Lilly and Company; AstraZeneca Inc.; Boehringer Ingelheim International GmbH; Hanmi Pharm Co. Ltd.; Pfizer Inc.; Amgen Inc.; Innovent Biologics Inc.; Jiangsu Hengrui Medicine Co.; Sun Pharmaceuticals Industries Ltd.; PegBio Co. Ltd.; Zealand Pharma A/S; Bristol-Myers Squibb Company; Chongqing Lummy Pharmaceutical Co. Ltd.; Daiichi Sankyo Company Limited; Dong-A ST Co. Ltd.; Eisai Co. Ltd.; HanAll Biopharma Co. Ltd.; Ipsen SA; Johnson & Johnson; Merck & Co. Inc.; Novartis AG.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report
+ Excel Dashboard
Added Benefits
Bi-Annual Data Update
Customisation
Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.

Product Code: PH5MG1RA01_G26Q1

1. Executive Summary

1.1. Key Market Insights (2020-2035)
1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots
1.3. Major Factors Driving the Market
1.4. Top Three Trends Shaping the Market

2. GLP-1 Receptor Agonist Market Characteristics

2.1. Market Definition & Scope
2.2. Market Segmentations
2.3. Overview of Key Products and Services
2.4. Global GLP-1 Receptor Agonist Market Attractiveness Scoring And Analysis
- 2.4.1. Overview of Market Attractiveness Framework
- 2.4.2. Quantitative Scoring Methodology
- 2.4.3. Factor-Wise Evaluation
Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation

2.4.4. Market Attractiveness Scoring and Interpretation
2.4.5. Strategic Implications and Recommendations

3. GLP-1 Receptor Agonist Market Supply Chain Analysis

3.1. Overview of the Supply Chain and Ecosystem
3.2. List Of Key Raw Materials, Resources & Suppliers
3.3. List Of Major Distributors and Channel Partners
3.4. List Of Major End Users

4. Global GLP-1 Receptor Agonist Market Trends And Strategies

4.1. Key Technologies & Future Trends
- 4.1.1 Biotechnology, Genomics & Precision Medicine
- 4.1.2 Digitalization, Cloud, Big Data & Cybersecurity
- 4.1.3 Artificial Intelligence & Autonomous Intelligence
- 4.1.4 Industry 4.0 & Intelligent Manufacturing
- 4.1.5 Sustainability, Climate Tech & Circular Economy
4.2. Major Trends
- 4.2.1 Expansion Of Glp-1 Therapies Beyond Diabetes
- 4.2.2 Rising Demand For Long-Acting And Once-Weekly Formulations
- 4.2.3 Growth Of Oral Glp-1 Receptor Agonists
- 4.2.4 Increasing Focus On Weight Management Indications
- 4.2.5 Strategic Partnerships And Licensing Agreements

5. GLP-1 Receptor Agonist Market Analysis Of End Use Industries

5.1 Hospitals
5.2 Diabetes Specialty Clinics
5.3 Endocrinology Clinics
5.4 Ambulatory Care Centers
5.5 Home Healthcare Providers

6. GLP-1 Receptor Agonist Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global GLP-1 Receptor Agonist Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

7.1. Global GLP-1 Receptor Agonist PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
7.2. Global GLP-1 Receptor Agonist Market Size, Comparisons And Growth Rate Analysis
7.3. Global GLP-1 Receptor Agonist Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
7.4. Global GLP-1 Receptor Agonist Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global GLP-1 Receptor Agonist Total Addressable Market (TAM) Analysis for the Market

8.1. Definition and Scope of Total Addressable Market (TAM)
8.2. Methodology and Assumptions
8.3. Global Total Addressable Market (TAM) Estimation
8.4. TAM vs. Current Market Size Analysis
8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. GLP-1 Receptor Agonist Market Segmentation

9.1. Global GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Exenatide, Liraglutide, Dulaglutide, Lixisenatide, Other Drugs
9.2. Global GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Parenteral, Oral
9.3. Global GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Hospitals, Surgical Clinics, Other Users

10. GLP-1 Receptor Agonist Market Regional And Country Analysis

10.1. Global GLP-1 Receptor Agonist Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
10.2. Global GLP-1 Receptor Agonist Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific GLP-1 Receptor Agonist Market

11.1. Asia-Pacific GLP-1 Receptor Agonist Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
11.2. Asia-Pacific GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Segmentation By Route Of Administration, Segmentation By End Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China GLP-1 Receptor Agonist Market

12.1. China GLP-1 Receptor Agonist Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
12.2. China GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Segmentation By Route Of Administration, Segmentation By End Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India GLP-1 Receptor Agonist Market

13.1. India GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Segmentation By Route Of Administration, Segmentation By End Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan GLP-1 Receptor Agonist Market

14.1. Japan GLP-1 Receptor Agonist Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
14.2. Japan GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Segmentation By Route Of Administration, Segmentation By End Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia GLP-1 Receptor Agonist Market

15.1. Australia GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Segmentation By Route Of Administration, Segmentation By End Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia GLP-1 Receptor Agonist Market

16.1. Indonesia GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Segmentation By Route Of Administration, Segmentation By End Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea GLP-1 Receptor Agonist Market

17.1. South Korea GLP-1 Receptor Agonist Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
17.2. South Korea GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Segmentation By Route Of Administration, Segmentation By End Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan GLP-1 Receptor Agonist Market

18.1. Taiwan GLP-1 Receptor Agonist Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
18.2. Taiwan GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Segmentation By Route Of Administration, Segmentation By End Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia GLP-1 Receptor Agonist Market

19.1. South East Asia GLP-1 Receptor Agonist Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
19.2. South East Asia GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Segmentation By Route Of Administration, Segmentation By End Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe GLP-1 Receptor Agonist Market

20.1. Western Europe GLP-1 Receptor Agonist Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
20.2. Western Europe GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Segmentation By Route Of Administration, Segmentation By End Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK GLP-1 Receptor Agonist Market

21.1. UK GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Segmentation By Route Of Administration, Segmentation By End Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany GLP-1 Receptor Agonist Market

22.1. Germany GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Segmentation By Route Of Administration, Segmentation By End Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France GLP-1 Receptor Agonist Market

23.1. France GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Segmentation By Route Of Administration, Segmentation By End Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy GLP-1 Receptor Agonist Market

24.1. Italy GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Segmentation By Route Of Administration, Segmentation By End Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain GLP-1 Receptor Agonist Market

25.1. Spain GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Segmentation By Route Of Administration, Segmentation By End Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe GLP-1 Receptor Agonist Market

26.1. Eastern Europe GLP-1 Receptor Agonist Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
26.2. Eastern Europe GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Segmentation By Route Of Administration, Segmentation By End Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia GLP-1 Receptor Agonist Market

27.1. Russia GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Segmentation By Route Of Administration, Segmentation By End Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America GLP-1 Receptor Agonist Market

28.1. North America GLP-1 Receptor Agonist Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
28.2. North America GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Segmentation By Route Of Administration, Segmentation By End Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA GLP-1 Receptor Agonist Market

29.1. USA GLP-1 Receptor Agonist Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
29.2. USA GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Segmentation By Route Of Administration, Segmentation By End Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada GLP-1 Receptor Agonist Market

30.1. Canada GLP-1 Receptor Agonist Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
30.2. Canada GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Segmentation By Route Of Administration, Segmentation By End Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America GLP-1 Receptor Agonist Market

31.1. South America GLP-1 Receptor Agonist Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
31.2. South America GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Segmentation By Route Of Administration, Segmentation By End Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil GLP-1 Receptor Agonist Market

32.1. Brazil GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Segmentation By Route Of Administration, Segmentation By End Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East GLP-1 Receptor Agonist Market

33.1. Middle East GLP-1 Receptor Agonist Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
33.2. Middle East GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Segmentation By Route Of Administration, Segmentation By End Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa GLP-1 Receptor Agonist Market

34.1. Africa GLP-1 Receptor Agonist Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
34.2. Africa GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Segmentation By Route Of Administration, Segmentation By End Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. GLP-1 Receptor Agonist Market Regulatory and Investment Landscape

36. GLP-1 Receptor Agonist Market Competitive Landscape And Company Profiles

36.1. GLP-1 Receptor Agonist Market Competitive Landscape And Market Share 2024
- 36.1.1. Top 10 Companies (Ranked by revenue/share)
36.2. GLP-1 Receptor Agonist Market - Company Scoring Matrix
- 36.2.1. Market Revenues
- 36.2.2. Product Innovation Score
- 36.2.3. Brand Recognition
36.3. GLP-1 Receptor Agonist Market Company Profiles
- 36.3.1. Novo Nordisk A/S Overview, Products and Services, Strategy and Financial Analysis
- 36.3.2. Sanofi SA Overview, Products and Services, Strategy and Financial Analysis
- 36.3.3. Eli Lilly and Company Overview, Products and Services, Strategy and Financial Analysis
- 36.3.4. AstraZeneca Inc. Overview, Products and Services, Strategy and Financial Analysis
- 36.3.5. Boehringer Ingelheim International GmbH Overview, Products and Services, Strategy and Financial Analysis

37. GLP-1 Receptor Agonist Market Other Major And Innovative Companies

Hanmi Pharm Co. Ltd., Pfizer Inc., Amgen Inc., Innovent Biologics Inc., Jiangsu Hengrui Medicine Co., Sun Pharmaceuticals Industries Ltd., PegBio Co. Ltd., Zealand Pharma A/S, Bristol-Myers Squibb Company, Chongqing Lummy Pharmaceutical Co. Ltd., Daiichi Sankyo Company Limited, Dong-A ST Co. Ltd., Eisai Co. Ltd., HanAll Biopharma Co. Ltd., Ipsen SA

38. Global GLP-1 Receptor Agonist Market Competitive Benchmarking And Dashboard

39. Key Mergers And Acquisitions In The GLP-1 Receptor Agonist Market

40. GLP-1 Receptor Agonist Market High Potential Countries, Segments and Strategies

40.1 GLP-1 Receptor Agonist Market In 2030 - Countries Offering Most New Opportunities
40.2 GLP-1 Receptor Agonist Market In 2030 - Segments Offering Most New Opportunities
40.3 GLP-1 Receptor Agonist Market In 2030 - Growth Strategies
- 40.3.1 Market Trend Based Strategies
- 40.3.2 Competitor Strategies

41. Appendix

41.1. Abbreviations
41.2. Currencies
41.3. Historic And Forecast Inflation Rates
41.4. Research Inquiries
41.5. The Business Research Company
41.6. Copyright And Disclaimer